About: Linifanib

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Linifanib (ABT-869) is a structurally novel, potent inhibitor of receptor tyrosine kinases (RTK), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGF receptor beta (PDGFR-β), KDR, and colony stimulating factor 1 receptor (CSF-1R), respectively. It has much less activity (IC50s > 1 μM) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. In vivo linifanib is effective orally in mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50%inhibition, 15 mg/kg).

thumbnail
Property Value
dbo:abstract
  • Linifanib (ABT-869) is a structurally novel, potent inhibitor of receptor tyrosine kinases (RTK), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGF receptor beta (PDGFR-β), KDR, and colony stimulating factor 1 receptor (CSF-1R), respectively. It has much less activity (IC50s > 1 μM) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. In vivo linifanib is effective orally in mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50%inhibition, 15 mg/kg). (en)
dbo:casNumber
  • 796967-16-3
dbo:chEBI
  • 91435
dbo:chEMBL
  • 223360
dbo:fdaUniiCode
  • CO93X137CW
dbo:kegg
  • D09635
dbo:pubchem
  • 11485656
dbo:thumbnail
dbo:wikiPageID
  • 32610132 (xsd:integer)
dbo:wikiPageLength
  • 3027 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1083875369 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:c
  • 17 (xsd:integer)
dbp:casNumber
  • 796967 (xsd:integer)
dbp:chebi
  • 91435 (xsd:integer)
dbp:chembl
  • 223360 (xsd:integer)
dbp:chemspiderid
  • 9660475 (xsd:integer)
dbp:f
  • 1 (xsd:integer)
dbp:h
  • 15 (xsd:integer)
dbp:iupacName
  • 1 (xsd:integer)
dbp:iupharLigand
  • 5657 (xsd:integer)
dbp:kegg
  • D09635 (en)
dbp:legalStatus
  • Investigational (en)
dbp:n
  • 5 (xsd:integer)
dbp:o
  • 1 (xsd:integer)
dbp:pubchem
  • 11485656 (xsd:integer)
dbp:smiles
  • Cc1ccccc1 (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • MPVGZUGXCQEXTM-UHFFFAOYSA-N (en)
dbp:unii
  • CO93X137CW (en)
dbp:verifiedrevid
  • 416014858 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Linifanib (ABT-869) is a structurally novel, potent inhibitor of receptor tyrosine kinases (RTK), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGF receptor beta (PDGFR-β), KDR, and colony stimulating factor 1 receptor (CSF-1R), respectively. It has much less activity (IC50s > 1 μM) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. In vivo linifanib is effective orally in mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50%inhibition, 15 mg/kg). (en)
rdfs:label
  • Linifanib (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License